SCHEMBL5244572

SCHEMBL5244572

O=S(=O)(Nc1cc(Cl)ccc1Cl)c1cccc2nonc12

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.63
POLB P06746 3/20 0.63
CCKBR P32239 1/20 0.63
CCR1 P32246 1/20 0.62
CCR2 P41597 1/20 0.62
GFER P55789 1/20 0.60
ALDH1A1 P00352 5/20 0.59
MAPT P10636 2/20 0.59
LMNA P02545 1/20 0.59
GAA P10253 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MCL1 Q07820 1/20 0.56
MEN1 O00255 2/20 0.56
MAPK1 P28482 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ACLY P53396 1/20 0.54
NPC1 O15118 1/20 0.52
TASP1 Q9H6P5 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5244837 0.88 POLB (0.72) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL5282078 0.84 MCL1 (0.61) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL5243746 0.82 KMT2A (0.64) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL14433266 0.82 KMT2A (0.76) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL5281422 0.81 KMT2A (0.66) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL5246130 0.81 ALDH1A1 (0.69) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL6394115 0.78 KMT2A (0.64) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL5324041 0.78 KMT2A (1.00) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL20344347 0.76 ALDH1A1 (0.52) KMT2APOLBCCKBRCCR1CCR2
SCHEMBL14919762 0.76 MEN1 (0.73) KMT2APOLBALDH1A1GAAMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885POLB 2997/4885CCKBR 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.